Alexion Fires Back At Blood Drug Patent Invalidity Bid
Alexion Pharmaceuticals has denied claims by rival Amgen that a patent protecting its ultra-rare blood disorder drug Soliris is invalid, as Amgen looks to bring its own similar version of the...To view the full article, register now.
Already a subscriber? Click here to view full article